Biosimilar company Sandoz has announced the launch of a new global initiative to take on worldwide health inequities.
Act4Biosimilars aims to increase patient access to advanced medicines by leveraging the ‘4 As’ of biosimilars – approvability, accessibility, acceptability and affordability. The initiative is supported by a multidisciplinary steering committee of patient advocacy leaders, healthcare professionals, biosimilar experts and industry leaders from across the world.
Other notable targets of the project include ensuring equitable pricing, involving patients in treatment decisions and streamlining biosimilar development. The ultimate goal is to increase global adoption of biosimilar medicines by at least 30% throughout 30 countries by 2030.
“As a result of their affordability, biosimilars have opened up a new realm of possibility for patients by enabling biological medicines to become more widely available to those in need of these advanced, life-changing treatments,” explained Zorana Maravic, CEO at Digestive Cancers Europe. “However, until we address existing biosimilar access inequities, far too many patients will continue to miss out on treatment with the best possible medicines.”
“Healthcare systems are facing more pressure than ever before, which can be attributed to the costs associated with a growing, ageing population, more people being diagnosed with chronic diseases,” added Richard Saynor, chief executive officer at Sandoz. “Biosimilars are part of the solution to support a more sustainable healthcare system for all and we are proud to be the founding sponsor of Act4Biosimilars, which will drive action to bring these more affordable treatment options to patients who need them.”
The Steering Committee is currently developing an action plan to provide the strategies, tools and activities required to realise the global ambitions. This will be supported by country indicator maps to measure the change that is being driven by groups, associations and organisations worldwide.
A biosimilar is a biological medicine which is produced after the original therapy’s patent has expired. Biosimilars also match all the required treatment references in terms of quality, safety and efficacy.
Sandoz developed and brought the first biosimilar medicine to patients 16 years ago.
by John Pinching
After 14 regulatory approvals on three continents last year, UCB is positioned to grow for “a decade-plus,” CEO Jean-Christophe Tellier said in the company’s full-year earnings press release. Meanwhile, eight regulatory reviews are ongoing.
Vyvgart Hytrulo, the subcutaneous version of argenx’s FcRn blocker, is already approved in generalized myasthenia gravis (gMG). Supported by data published last year, the biotech has filed for approval in a second setting, chronic inflammatory demyelinating polyneuropathy (CIDP), and is now counting down the weeks until the FDA rules on its submission.
Overseeing the four-year plan, dubbed FOCUS-27, will be new chief executive officer Ludwig de Mot—an industry veteran with a track record at “companies undergoing transformation,” EuroAPI said in an earnings release Wednesday. De Mot, who will take up the reins on Friday, joined the company in January as EuroAPI’s chief transformation officer.